Spero Therapeutics
Myriah Satterfield has a diverse work experience spanning multiple companies and roles. Myriah started their career in 2003 as an Assistant Administrative for Nike Golf R&D at Adecco Staffing, USA. From 2003 to 2005, they worked as a Public Health Facilitator at Peace Corps, where they developed HIV/AIDS prospectus, trained health workers, collaborated with CDC, and established an income-generating project.
In 2006, Myriah joined Alcon, a Novartis company, where they worked in various roles, including Clinical Data Associate I and II, Senior CDM Manager, and Lead CDM Data Manager. Myriah then moved to Theorem (now Chiltern) and worked as a Senior Clinical Data Manager and Senior Clinical Data Manager (Biomarker). Following this, they joined Chiltern (formerly Theorem) as a Project Data Manager (Biomarker) for a short period of time in 2015.
In 2016, Myriah joined Ultragenyx Pharmaceutical Inc. as a Manager, Clinical Data Management, where they worked until 2019. Myriah then transitioned to Spero Therapeutics, where they held multiple roles, including Manager Clinical Data Management, Senior Manager, Clinical Data Management, and their current role as Associate Director, Clinical Data Management, starting in 2023.
Overall, Myriah has built a strong background in clinical data management, with experience in project management, biomarkers, and leadership positions.
Myriah Satterfield attended Tarleton State University from 1996 to 2000, where they earned a Bachelor of Science (BS) degree in Pre-Medicine/Pre-Medical Studies.
This person is not in the org chart
This person is not in any offices
Spero Therapeutics
2 followers
Spero Therapeutics (Nasdaq: SPRO) is a multi-asset pre-commercial stage biopharmaceutical company in Cambridge, Mass. We are highly committed to advancing novel treatment approaches for bacterial infections with a world-class team of biotechnological and biopharmaceutical experts. The company has a pipeline of novel and highly differentiated antibacterial and rare disease product candidates focused on patients' unmet needs with multi-drug resistant (MDR) bacterial infections.